Trial Profile

A Phase 2 Study of XL147 (SAR245408) in Subjects With Advanced or Recurrent Endometrial Carcinoma

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 04 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pilaralisib (Primary)
Indications Endometrial cancer
Focus Adverse reactions; Proof of concept; Therapeutic Use
Sponsors Sanofi

Most Recent Events

02 Apr 2022 This trial has been completed in France, according to European Clinical Trials Database record.
08 Jan 2013 Status changed from recruiting to discontinued, according to a Sanofi media release.
20 Jun 2012 Planned End Date changed from 1 Mar 2013 to 1 Sep 2013 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com